Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-25
2007-09-25
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
10988847
ABSTRACT:
Treatment and/or inhibition of renal dysfunction, disease or disorder in larger mammals, and particularly in humans, especially in human patients suffering from diabetes, using benzazepine-N-acetic acid derivatives which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or salts or biolabile esters or physiologically acceptable solvates thereof, and production of pharmaceutical compositions and products suitable for treatment and/or inhibition of renal dysfunction, disease or disorder, particularly in diabetic patients, but also in patients with syndrome X or in patients with a renal dysfunction, disease and/or disorder, which patients are additionally hypertensive, obese, hyperglycemic and/or subject to a metabolic disorder.
REFERENCES:
patent: 5677297 (1997-10-01), Waldeck et al.
patent: 5783573 (1998-07-01), Rozsa et al.
patent: 6482820 (2002-11-01), Wilkins et al.
patent: 6906059 (2005-06-01), Rozsa et al.
patent: 195 10 566 (1995-03-01), None
patent: 0 733 642 (1996-03-01), None
patent: WO 00/48601 (2000-08-01), None
patent: WO 01/03699 (2001-01-01), None
patent: WO 01/15673 (2001-03-01), None
patent: WO 03/059939 (2003-07-01), None
patent: WO 03/097067 (2003-11-01), None
“Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes”, Iikka Tikkanen et al; Journal of Hypertension 2002, vol. 20, No. 4, pp. 707-714.
“Effects of Endothelin Receptor Antagonists on the Progression of Diabetic Nephropathy”, Berthold Hocher et al; Nephron 2001; 87; pp. 161-169.
“Renal Endothelin System in Diabetes: Comparison of Angiotensin-Converting Enzyme Inhibition and Endothelin-A Antagonism”; Berthold Hocher et al; Journal of Cardiovascular Pharmacology; 31 (Supp 1) pp. 5492-5495; 1998.
(SLV-306) “Antihypertensive Treatment of Hear tFailure Neprilysin Inhibitor Endothelin-Converting Enzyme Inhibitor” I.A. Sorbera et al; Drugs of the Future 2002 27(1) p. 27-31.
“Urinary Protein as Measured with a Pyrogallot Red-Molybdate Complex, Manually and in a Hitachi 726 Automated Analyzer”; Nobuko Watanabe et al; Clinical Chemistry, vol. 32, No. 8, 1986, pp. 1551-1544.
Partial European Search Report, for EP 03 10 4264, Mar. 17, 2004.
Hocher Berthold
Thormaehlen Dirk
Waldeck Harald
Crowell & Moring LLP
Henley, III Raymond J
Solvay Pharmaceuticals GmbH
LandOfFree
Method and pharmaceutical compositions for treating or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and pharmaceutical compositions for treating or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and pharmaceutical compositions for treating or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790740